Radiopharmaceuticals have gained considerable interest in the investment community recently, with the advent of innovative therapeutics such as Alpharadin^® of Bayer, an alpha-emitter based treatement for prostate cancer, due for marketing authorisation by end 2012, or new radiopharmaceutical PET imaging agents, such as the Alzheimer agent Florbetapir^® of AVID pharmaceuticals, licensed in April 2012, having been the key component of Lilly´s $ 800 million acquisition of AVID by Eli Lilly in late 2010.

Radiopharmaceuticals, due to their particle emission allow direct assessment of pharmacokinetics (distribution in the body) and target uptake (e.g. into tumour) by imaging methodologies such as PET (positron emission tomography) or SPECT (single photon computed tomography).

For both, the therapeutic agent 131I-ACD-101 and the diagnostic agent 124-ACD-101 tumour targeting and efficacy have been demonstrated, minimizing the development risk, compared to conventional drug candidates

The existing pharmacokinetic, dosimetric and pharmacodynamic data on ACD-101 demonstrate, that tumoricidic doses of 131I-ACD-101 can be administered to humans with an acceptable safety profile. First human therapies on compassionate use basishave shown very encouraging results.

ACD-101 is a small molecule. It is radioactively labeled with 131I for therapy (131I-ACD-101) :

Radiotoxicity + radiosensitiser effect + cytostatic effect
Highly specific glioma targeting, intracellular uptake and retention
Universal glioma affinity (WHO grade I – IV)
Ability to induce necrosis and apoptosis in glioma cells
Proven histological tumor clearance in vivo (RNU rat)
Allows for endoradiotherapy (ERT) using systemic administration (I.V.)
Fits into current treatment schedules, synergistic to these

and with 124I as a PET tracer for diagnosis (124I-ACD101):

Universal glioma affinity (WHO grade I – IV)
Optimised supply chain through centralize manufacturing
Comprehensive human patient data available

Please contact us for more details. We are open to interesting partnership propositions worldwide. Please use our contact side choosing "investment". We look forward to getting in touch with you!

Contact Therapeia

Therapeia GmbH & Co. KG
Veilchenweg 38
01326 Dresden
Germany

Tel: +49 (0)351 4188 00000
Fax: +49 (0)351 4188 00009

E-Mail: info@therapeia.info

or just use our contact form

Investor Center

Contact Therapeia

Login